OSLO, Norway, March 23, 2020 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that Dr Dominic
Smethurst has been appointed Interim Chief Medical Officer
with immediate effect. Dr Smethurst replaces Dr Lisa Rojkjaer, MD, who after a handover period
will leave Nordic Nanovector to pursue other career
opportunities.
Dr Smethurst is an experienced drug development physician having
led complex global clinical trials within oncology. Previously, Dr
Smethurst was the Group Medical Director of Tusk Therapeutics,
where he played a key role in the development of this private
immuno-oncology company focused on therapeutic antibodies. Tusk
Therapeutics was acquired by Roche for potentially €655 million in
September 2018.
Prior to Tusk, Dr Smethurst has held senior roles at Icon, a
global Contract Research Organisation (CRO), where he was VP
Oncology Global Therapeutic Area Lead and at
Adaptimmune/Immunocore, where he was CMO. Dr Smethurst has also
worked for Amgen and AstraZeneca in medical roles of increasing
seniority.
Dr Smethurst gained his medical qualifications, at the
Addenbrooke's Clinical School (Cambridge,
UK). He is member of both the Royal College of Physicians
(UK) and the Faculty of Pharmaceutical Medicine (UK).
Dr Lars Nieba, Interim CEO of
Nordic Nanovector, commented: "I am pleased that we have been able
to appoint Dominic as our new Interim CMO. He is a very experienced
and commercially focused medical physician with significant
clinical development skills, and I am sure his input will be of
great value as we work together to complete the PARADIGME study and
to prepare for the planned filing for Betalutin® in the US. I would
like to take this opportunity to thank Lisa for her contribution in
advancing the clinical development of Betalutin®."
Dr Dominic Smethurst, Interim CMO
of Nordic Nanovector, said: "I am looking forward to joining at
this critical time for Nordic Nanovector as it seeks to complete
the pivotal trial PARADIGME with Betalutin® in a timely manner. I
believe it is important that we can bring Betalutin® to patients
with advanced follicular lymphoma given the very promising efficacy
data that has been generated alongside a favourable safety profile
and convenient once-only dosing regimen."
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains
global marketing rights to Betalutin® and intends to actively
participate in the commercialisation of Betalutin® in the US and
other major markets.
Further information can be found at
www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Sections 4-2 and 5-12 of the Securities Trading Act.
CONTACT:
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer
Hall/David Dible (Citigate Dewe
Rogerson)
Tel: +44-203-926-8535
Email: nordicnanovector@citigatedewerogerson.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-dr-dominic-smethurst-as-interim-chief-medical-officer,c3066481